Manuscripts, Figures, Photographs & Tables

Manuscripts: Microsoft Word is the preferred document format. Please do not center (fully justify) text and please do not enable line numbering. Do not use end-note or foot-note utilities, as manuscripts using these utilities may be returned. Please provide full affiliation information for each author and full, detailed author-specific conflict of interest disclosures; if nothing to disclose, please so state.

Figures/drawings: Submit graphs and drawings in TIFF, JPG, PDF, or PPT format.

Photographs: JPG is the preferred format for photographs; resolution 300 dpi or higher; CMYK or grayscale color space; image size at least 3.5″ wide. Identify the figure number and the corresponding author in the filename.

Tables: Preferred format is Microsoft Word or Excel. Do not embed as an image.

N.B. All figures and photographs should be submitted as separate files in their source application; do not embed them in a text document.

Limited Copyright Transfer Agreement

In order to proceed with the peer review process, the Submitting Author must complete and sign the Limited Copyright Transfer Agreement. This form transfers copyright from authors to the Journal of Drugs in Dermatology only if the submission has been accepted for publication.

Style

Please consult the latest editions of the AMA Manual of Style, Merriam-Webster’s Collegiate Dictionary, and Stedman’s Medical Dictionary for the proper expression of numbers, punctuation, spelling, referencing, and all other matters of style.

A title page is to be provided and should include the title of the article, author names, highest level medical degrees, and author affiliations. The affiliation should designate the department, institution (usually university or company), city and state (or nation). For administrative purposes, the title page should include the complete mailing address, telephone number, and e-mail address of the corresponding author authorized to review proofs or confirm revisions, if necessary. The title page must also disclose any relevant conflicts of interest, financial or otherwise.

An abstract is to be provided, <250 words. Please use only 1 space after periods at the ends of all sentences. Headers should either be bold or bold italics, not in all capitals.

Illustrations (photographs, drawings, diagrams, tables, and charts) are each to be numbered in 1 consecutive series of Arabic numerals (eg, Figures 1 and 2; Tables 1 and 2). Figure legends (sentence case) and Table titles (capitalized) should be listed sequentially at the end of the main document. All illustrations must be complete and final, ie, publication-ready.

Please disclose all relevant conflicts of interest at the end of the article.

References

Following the AMA Manual of Style, each reference should be cited in the text with a superscripted Arabic numeral, following punctuation, and corresponding to the numeral listed sequentially in the reference list at the end of the article (eg, as shown in the prior study.¹). If there are more than 4 authors for a reference, list the first 3 followed by et al. in accordance with the punctuation below. Do not use the insert footnotes function in Microsoft Word.

Journal Article

Ito T, Moore JI, Koss MC. Topical application of CO₂ increases skin blood flow. J Invest Dermatol. 1989;93:259-262.

Book

Goodman A, Goodman L, Gilman A. The Pharmacologic Basis of Therapeutics. 6th ed. New York: Macmillan. 1980.

Chapter in a Book

Pathak M, Fitzpatrick T. Preventative treatment of sunburn, dermatophilosis, and skin cancer with sun-protective agents. In: Fitzpatrick T, Eisen A, Wolffe K, eds. Dermatology in General Medicine. 4th ed. New York, NY: McGraw-Hill. 1993:1689-1717.

Website

National Psoriasis Foundation. Statistics. Available at: http://www.psoriasis.org/about/stats/. Accessed July 17, 2006.

Package Insert

Lamasil [package insert]. East Hanover, NJ: Sandoz PharmaceuticalsCorp; 1993.

Note: Use of the aforementioned style guides does not signify an endorsement of said products. Please do your best to follow the instructions herein, or your submission may be rejected.

Disclosure Policy

The JDD disclosure policy is for authors to provide full detailed conflict of interest disclosures. Authors should disclose any commercial or proprietary interests in any drug, device, method, product, or equipment mentioned in the submission or if there are any other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, the submitted work. If at any time, they received payments or services from a third party for any aspect of the submitted work, including grants, personal fees, non-financial support, or other conflicts of interest, it should be stated. Authors understand and agree that such disclosure will identify any financial interest in any items mentioned in the submission.

For each author, a statement that mentions any potential perceived conflicts of interest and/or relevant financial relationships should be included under the heading of Disclosure or it should be stated if the author has no conflicts.

Duplicate Publication, Redundant Publication

Any manuscript submitted to JDD must be original and the manuscript, or substantial parts of it, must not be under consideration by any other journal. In any case where there is the potential for overlap or duplication, we require that authors are transparent. Authors should declare any potentially overlapping publications upon submission. Any overlapping publications relevant to the Editor’s and reviewers’ assessment of the manuscript, should be made available if requested by the Editor. JDD reserves the right to judge potentially overlapping or redundant publications on a case-by-case basis.